Cost Is One of the Biggest Barriers to Insulin Adherence—Here's How You Can Help

For patients prescribed Levemir (Insulin Detemir), the cost of medication can be the difference between consistent diabetes management and dangerous gaps in treatment. As a prescriber, you're in a unique position to connect patients with savings programs, discuss lower-cost alternatives, and build cost conversations into your clinical workflow.

This guide provides a practical overview of the financial landscape for Levemir in 2026—including what patients are actually paying, which savings programs are still active, and when therapeutic substitution makes clinical sense.

What Patients Are Paying for Levemir

The financial burden of Levemir varies significantly depending on insurance status:

• Cash price (uninsured): Approximately $350 to $500 per box of 5 FlexTouch pens (15 mL total) or per 10 mL vial
• Commercially insured: Copays range from $25 to $150+ depending on formulary tier and plan design. Many plans have moved Levemir to higher tiers or removed it entirely due to the discontinuation.
• Medicare Part D: Coverage varies by plan. Some Part D formularies still include Levemir, though prior authorization or step therapy (typically trying Insulin Glargine first) may be required. The Inflation Reduction Act's $35/month insulin cap applies to Medicare beneficiaries and has helped some patients.
• Uninsured or underinsured: These patients face the full cash price and are most at risk for non-adherence or rationing.

A 2023 survey by the American Diabetes Association found that one in four insulin users reported rationing their insulin due to cost. For your patients on Levemir—a medication with no generic or biosimilar equivalent and a diminishing supply—cost pressure is particularly acute.

Manufacturer Savings Programs

NovoCare Levemir Savings Card

Novo Nordisk previously offered a copay savings card through NovoCare that could reduce out-of-pocket costs to as low as $25 per prescription for eligible commercially insured patients. However, due to Levemir's planned discontinuation, this program may no longer be available. Verify current status at novocare.com before directing patients to apply.

Novo Nordisk Patient Assistance Program (PAP)

For uninsured patients who meet income requirements (typically under 400% of the federal poverty level), the Novo Nordisk PAP provides free insulin. This is one of the most impactful programs for eligible patients.

• Application: Available at novocare.com or by calling 1-866-310-7549
• Eligibility: US residents, no insurance (or insurance that doesn't cover the medication), income-qualified
• What it provides: Free Levemir for qualifying patients, typically for a set period with option to reapply

The PAP is still operational as of early 2026, though it may wind down as Levemir supply is exhausted. Encourage eligible patients to apply sooner rather than later.

Coupon and Discount Cards

For patients who don't qualify for manufacturer programs, third-party discount cards can provide meaningful savings:

• GoodRx — Aggregates prices across pharmacies and offers coupons. Levemir prices through GoodRx vary by pharmacy but can save 10-30% off cash price. Available at goodrx.com.
• SingleCare — Similar model to GoodRx with competitive pricing at many pharmacies. Check singlecare.com.
• RxSaver — Pharmacy price comparison tool that shows discount prices. Visit rxsaver.com.
• Inside Rx — Backed by Express Scripts, offers discounts on brand-name medications. Check insiderx.com.

Important note for your workflow: These discount cards cannot be combined with insurance. They're most useful for patients paying cash or those whose insurance copay exceeds the discount card price.

For a comprehensive patient-facing guide, refer patients to our article on how to save money on Levemir.

Additional Assistance Resources

• NeedyMeds (needymeds.org) — Database of patient assistance programs, state programs, and discount drug cards
• RxAssist (rxassist.org) — Comprehensive database of patient assistance programs
• RxHope (rxhope.com) — Helps patients and providers navigate manufacturer assistance programs

Generic Alternatives and Therapeutic Substitution

There is no generic or biosimilar version of Levemir currently available. However, given the ongoing discontinuation, therapeutic substitution is increasingly necessary—and may also provide cost savings for patients.

Long-Acting Insulin Alternatives

• Insulin Glargine (Lantus) — The most established alternative. Biosimilars available (Basaglar, Semglee) at approximately $150 to $300 per box—significantly less than Levemir's $350-$500 cash price.
• Insulin Glargine-yfgn (Semglee) — An interchangeable biosimilar of Lantus. Often the most cost-effective long-acting insulin option. Interchangeable status means pharmacists can substitute without a new prescription in most states.
• Insulin Glargine (Basaglar) — Another biosimilar of Lantus, widely available and typically well-covered by insurance.
• Insulin Degludec (Tresiba) — Ultra-long-acting insulin (>42 hours) with flexible dosing. More expensive than biosimilar glargines but may offer clinical advantages for patients with hypoglycemia unawareness or irregular schedules.
• NPH Insulin (Humulin N, Novolin N) — Intermediate-acting, significantly cheaper (as low as $25-$50 per vial at some retailers), and available OTC. However, it has a more pronounced peak and less predictable profile, requiring more patient education and monitoring.

Clinical Considerations for Switching

When transitioning patients from Levemir to an alternative:

• Levemir to Insulin Glargine (once daily): Generally a unit-for-unit conversion for patients on once-daily Levemir. For patients on twice-daily Levemir, total the daily dose and start glargine at 80% of that total as a once-daily dose. Titrate based on fasting blood glucose.
• Levemir to Tresiba: Start at the same unit dose, administered once daily. Tresiba's longer duration means less dose-timing sensitivity.
• Levemir to NPH: This is not a simple switch. NPH has a different pharmacokinetic profile (shorter duration, pronounced peak). Expect to increase monitoring frequency and provide additional patient education. Dose conversion is approximately unit-for-unit but should be titrated carefully.

For a detailed comparison of alternatives, see our clinical guide on the Levemir shortage for providers and our patient-facing alternatives guide.

Building Cost Conversations Into Your Workflow

Many patients don't bring up cost concerns unless asked directly. Integrating cost discussions into your standard workflow can improve adherence and outcomes:

At Prescribing

• Ask about insurance coverage before writing the prescription. A quick "What does your insurance look like for insulin?" can save the patient a surprise at the pharmacy.
• Check formulary status using your EHR's formulary tools or by asking the patient to call their insurance. Prescribing a preferred formulary insulin reduces cost and prior authorization delays.
• Default to biosimilars when appropriate — For new insulin starts, consider prescribing Insulin Glargine (Basaglar or Semglee) instead of brand-name options when clinically equivalent.

At Follow-Up

• Ask directly: "Are you having any trouble affording your insulin?" or "Have you ever skipped or rationed doses because of cost?"
• Screen for non-adherence patterns that may signal cost barriers: A1C rising despite stable lifestyle, running out of insulin before refill, inconsistent refill history.
• Provide resources proactively — Have printed or digital handouts with links to savings programs, PAPs, and discount cards. Consider adding Medfinder for Providers to your workflow to help patients locate medications in stock.

In Your Practice

• Train front office staff to ask about medication cost concerns during intake.
• Designate a team member (nurse, MA, social worker) to assist with PAP applications and discount card enrollment.
• Keep a quick-reference list of insulin cost resources (manufacturer programs, discount cards, PAP contacts) accessible to clinical staff.

The Bigger Picture: Levemir Discontinuation

The Levemir discontinuation adds urgency to these conversations. Patients who have been stable on Levemir for years may resist switching, but proactive transition planning—combined with addressing cost concerns for the new medication—leads to better outcomes than an emergency switch when the pharmacy can't fill the script.

For patients who still need Levemir in the short term, Medfinder for Providers can help you and your patients locate pharmacies that currently have it in stock. For clinical guidance on managing the transition, see our provider's guide to finding Levemir.

Final Thoughts

Cost-related non-adherence is a clinical problem, not just a financial one. When patients ration insulin because they can't afford it, the downstream costs—in hospitalizations, complications, and lost quality of life—far exceed the price of the medication.

By proactively connecting patients with savings programs, considering lower-cost therapeutic alternatives, and normalizing cost conversations in your practice, you can help ensure that your patients on Levemir (or its successors) maintain consistent, safe diabetes management.

Visit Medfinder for Providers to learn how we can help your practice support patients with medication access and affordability.